Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May;14(3):156-60.
doi: 10.1080/13547500902773896.

Plasma levels of S100A4 in portopulmonary hypertension

Tien Peng  1 , Roham Zamanian, Michael J Krowka, Raymond L Benza, Kari E Roberts, Darren B Taichman, Debbie Rybak, James F Trotter, Robert S Brown Jr, Michael B Fallon, Steven M Kawut; Pulmonary Vascular Complications of Liver Disease Study Group
Collaborators, Affiliations

Plasma levels of S100A4 in portopulmonary hypertension

Tien Peng et al. Biomarkers. 2009 May.

Abstract

We previously showed that a single nucleotide polymorphism in S100A4 was associated with portopulmonary hypertension (PPHTN) in patients with advanced liver disease. We aimed to determine the association between plasma levels of S100A4 and PPHTN. We performed a case-control study of patients with advanced liver disease. Cases with PPHTN had mean pulmonary artery pressure >25 mmHg, pulmonary vascular resistance >240 dynes s cm(-5) and pulmonary capillary wedge pressure </=15 mmHg. Controls with liver disease had right ventricular systolic pressure <40 mmHg and normal right atrial and ventricular morphology by echocardiography. Plasma samples were assayed for S100A4. The study sample included 14 cases with PPHTN and 32 controls with liver disease. There was no difference in mean age between cases and controls (p = 0.52). Seventy-nine percent of cases were female compared with 44% of controls (p = 0.03). There was no difference in S100A4 levels between cases and controls (p = 0.58). Both groups had significantly higher S100A4 levels than healthy volunteers (p <0.05). There was no significant difference in plasma levels of S100A4 between PPHTN patients and controls with liver disease, although liver disease itself was associated with increased S100A4 levels.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: SMK has received lecture fees, consultancy fees, and/or other support from Actelion, Pfizer, Gilead, Lilly, Novartis, INO Therapeutics, United Therapeutics, Gerson Lehrman, and Clinical Advisors. MJK has provided consultation regarding possible clinical trials concerning portopulmonary hypertension for Gilead, United Therapeutics, and Actelion. Other authors have not declared a potential conflict of interest.

Figures

Figure 1
Figure 1
S100A4 level according to disease status (A) and genotype (B). Genotypes include one patient homozygous for the minor allele (CC), patients heterozygous for the minor allele (CG), and patients without the minor allele (GG). Black bar represents median plasma concentration. White box represents interquartile range.
Figure 1
Figure 1
S100A4 level according to disease status (A) and genotype (B). Genotypes include one patient homozygous for the minor allele (CC), patients heterozygous for the minor allele (CG), and patients without the minor allele (GG). Black bar represents median plasma concentration. White box represents interquartile range.
See this image and copyright information in PMC

References

    1. Greenway S, van Suylen RJ, Du Marchie Sarvaas G, Kwan E, Ambartsumian N, Lukanidin E, Rabinovitch M. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am J Pathol. 2004 Jan;164(1):253–62. - PMC - PubMed
    1. Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, Jones DE, Burt AD, Kirby JA. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest. 2008 Feb;88(2):112–23. - PubMed
    1. Lawson WE, Polosukhin VV, Zoia O, Stathopoulos GT, Han W, Plieth D, Loyd JE, Neilson EG, Blackwell TS. Characterization of fibroblast-specific protein 1 in pulmonary fibrosis. Am J Respir Crit Care Med. 2005 Apr 15;171(8):899–907. - PubMed
    1. Garrett SC, Varney KM, Weber DJ, Bresnick AR. S100A4, a mediator of metastasis. J Biol Chem. 2006 Jan 13;281(2):677–80. - PubMed
    1. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):5S–12S. - PubMed